FDA Ruling On Avastin A 'Critical Test' For Agency, New York Times Editorial Says
 

The recent "flameout" of the breast cancer drug Avastin "will pose a critical test" on whether FDA will "have the courage to reverse course when a medical treatment that it approved based on preliminary evidence flops badly in follow-up studies," the New York Times says in an editorial...

More...